Cyfuse Biomedical K.K. (TYO:4892)
Japan · Delayed Price · Currency is JPY 651.00
-25.00 (-3.70%)
Jan 21, 2026, 3:30 PM JST
Cyfuse Biomedical K.K. Revenue
Cyfuse Biomedical K.K. had revenue of 32.00M JPY in the quarter ending September 30, 2025, with 300.00% growth. This brings the company's revenue in the last twelve months to 89.00M, up 53.45% year-over-year. In the year 2024, Cyfuse Biomedical K.K. had annual revenue of 54.00M, down -11.48%.
Revenue (ttm)
89.00M
Revenue Growth
+53.45%
P/S Ratio
60.75
Revenue / Employee
4.24M
Employees
21
Market Cap
5.41B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 54.00M | -7.00M | -11.48% |
| Dec 31, 2023 | 61.00M | -313.00M | -83.69% |
| Dec 31, 2022 | 374.00M | -334.00M | -47.18% |
| Dec 31, 2021 | 708.00M | 571.00M | 416.79% |
| Dec 31, 2020 | 137.00M | 15.19M | 12.47% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pharma Foods International | 66.38B |
| Fuso Pharmaceutical Industries,Ltd. | 62.05B |
| Nippon Chemiphar | 32.88B |
| Morishita Jintan | 12.90B |
| Wakamoto Pharmaceutical | 9.43B |
| Taiko Pharmaceutical | 5.94B |
| WDB coco | 5.14B |
| SymBio Pharmaceuticals | 1.53B |